Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7009789 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I (Dose-Finding Stage) | EXPERIMENTAL | Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent. |
| Part II (Dose Expansion Stage) | EXPERIMENTAL | Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| Emactuzumab | DRUG | Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II. |
| RO7009789 | DRUG | RO7009789 will be administered IV every 3 weeks (every cycle). |
Inclusion Criteria: * Eastern Cooperative Oncology Group performance status 0 or 1 * Histologically confirmed diagnosis of locally advanced, recurrent, and/or metastatic triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, melanoma, or mesothelioma * ...